Recombinant Anti-CCR3 x Anti-CD300 Bispecific Antibody (scFv-CH1/CL) is designed to be expressed as two chains. One scFv from an anti-CCR3 antibody variable domain is fused to CH1 and the other scFv from an anti-CD300 antibody variable domain fused to CL, or vice versa. And the CH1 and CL domains are linked covalently via a natural disulfide bond. This BsAb canreduce eosinophil signaling, inhibit bronchoalveolar lavage fluid inflammation, eosinophil, mast cell mediator release and reverse lung inflammation. It is designed for the research of Asthma therapy.